WG
NRIX icon

Winton Group’s Nurix Therapeutics NRIX Stock Holding History

Winton Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,509
Closed -$333K – 1098
2021
Q4 		$333K Sell
11,509
-2,150
-16% -$65.2K 0.02% 799
2021
Q3 		$409K Buy
+13,659
New +$422K 0.02% 961

Other funds holding NRIX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Winton Group's NRIX Position: Q1 2022 in Review

Winton Group sold out of Nurix Therapeutics (NRIX) in Q1 2022, closing a stake of 11,509 shares — an estimated $333K sold.

Winton Group first reported a position in NRIX in Q3 2021 and held it in 2 quarters. The position peaked at $409K in Q3 2021. 117 funds tracked by Wall St. Rank hold NRIX as of Q1 2022.

  • Winton Group reported no remaining Nurix Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Winton Group sold 11,509 Nurix Therapeutics shares in Q1 2022, an estimated $333K.
  • Winton Group first reported a position in Nurix Therapeutics in Q3 2021 and held it in 2 quarters.
  • Winton Group's Nurix Therapeutics position peaked at $409K in Q3 2021.
  • 117 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2022.

Based on Winton Group's 13F filing for Q1 2022, filed 11 May 2022.